The molecular elucidation of FASN—a biological determinant of HER2 signaling-driven endocrine resistance in ER+ breast cancer—might accelerate new studies aimed to confirm whether FASN expression status might be employed as a useful and predictive biomarker of endocrine treatment for luminal B-like breast cancer. Here, ERBB2 is linked to breast carcinoma.